Press Releases

57_IGC-Pharma-Announces-Coverage-Report-by-Ascendiant-Capital-Marketsjpg
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50.” 
Read More →
56_IGC-Pharma-Expands-CALMA-Phase-2-Trial
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City 
Read More →
55_IGC-Pharma-Reports-First-Quarter-Fiscal-2026-Financial-Results
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer’s Trial
Read More →
54_IGC-Pharma-Unveils-Groundbreaking-Preclinical--in-vitro
IGC Pharma Highlights Alzheimer’s Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 
Read More →
53-IGC-Pharma-Reports-In-Vitro-Efficacy-of-Molecule-M3
IGC Pharma Reports IGC-M3’s In Vitro Efficacy Against Alzheimer’s – Targeting key Drivers of Disease Progression
Read More →
IIGC-Pharma-to-Present-Three-Posters-on-Artificial-Intelligence
IGC Pharma to Present Advanced AI Platforms for Alzheimer’s Disease at the AAIC 2025
Read More →
IGC-Pharma-Alzheimers-Jag-Rao
IGC Pharma’s Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
Read More →
IGC-Pharma-Introduces-MINT-AD
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer’s Risk and Accelerate Early Detection
Read More →
IGC-Reports-Financial-Results-for-Fiscal-Year-Ended-March-31,-2025
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation
Read More →
IGC-Pharma-Host-Fiscal-Year-June-25-2025 (1)
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30, 2025
Read More →
IGC-Pharma-Expands-CALMA-Trial-to-Oklahoma
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon 
Read More →
IGC-Pharma-Calma-Phase2-Alzheimer’s-Market
IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market
Read More →
IGC-Pharma-Alzheimers-Melatonin-Toxicity-Safety
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
Read More →
IGC-Pharma-Alzheimers-Innovation-AI-Advisory (2)
IGC Pharma Welcomes Strategic Investment from Advisors
Read More →
IGC-Pharma-Alzheimers-Innovation-AI-Advisory
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer’s Innovation and AI-Driven Programs  
Read More →
IGC-Pharma-Alzheimers-Butler-Hospital-Aging
IGC Pharma Expands CALMA Alzheimer’s Phase 2 Trial with Prestigious Research Site at Butler Hospital’s Memory and Aging Program  
Read More →